Advertisement

Organisation › Details
Idorsia Ltd. (SIX: IDIA)
Idorsia Ltd is reaching out for more - We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this we will develop Idorsia into Europe's leading biopharmaceutical company, with a strong scientific core. Headquartered in Switzerland - a European biotech hub - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully-functional research center, and a strong balance sheet - the ideal constellation to bringing R&D efforts to business success. Idorsia was listed on SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 600 highly qualified specialists dedicated to realizing our ambitious targets. *
![]() |
Start | 2017-03-02 established |
Group | Idorsia (Group) | |
Predecessor | Actelion Ltd. (SIX: ATLN) | |
![]() |
Industry | pharmaceutical |
![]() |
Person | Clozel, Jean-Paul (Idorsia 20403 CEO + Co-Founder before Actelion) |
Person 2 | Muller, André C. (Idorsia 202407 CEO formerly CFO before Actelion 201309– CFO before Pierre Fabre CFO) | |
![]() |
Region | Allschwil BL |
Country | Switzerland | |
Street | 91 Hegenheimermattweg | |
City | 3123 Allschwil BL | |
Tel | +41-58-844-0000 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | E: 501 to 1,000 (2019-12-31) |
Currency | CHF | |
Annual sales | 24,000,000 (revenue, total, consolidated (2019) 2019-12-31) | |
Profit | -494,000,000 (2019-12-31) | |
Cash | 263,000,000 (2019-09-30) | |
* Document for »About Section«: | ||
Record changed: 2024-12-31 |
Advertisement

More documents for Idorsia (Group)
- [1] Idorsia Ltd.. (12/20/24). "Press Release: Idorsia Provides Update on the Exclusive Negotiations for the Global Rights to Aprocitentan". Allschwil....
- [2] Idorsia Ltd.. (11/27/24). "Press Release: Idorsia Enters into Exclusive Negotiations for Global Rights to Aprocitentan". Allschwil....
- [3] Idorsia Ltd.. (7/1/24). "Press Release: Idorsia’s Jeraygo (aprocitentan) Approved in Europe as First and Only ERA for the Treatment of Resistant Hypertension". Allschwil....
- [4] Idorsia Ltd.. (4/11/24). "Press Release: Idorsia Takes Steps to Address Short-term Liquidity Needs". Allschwil....
- [5] Idorsia Ltd.. (3/20/24). "Press Release: US FDA Approves Idorsia’s Once-daily Tryvio (aprocitentan) – the First and Only Endothelin Receptor Antagonist for the Treatment of High Blood Pressure Not Adequately Controlled in Combination with other Antihy...
- [6] Idorsia Ltd.. (3/18/24). "Press Release: Idorsia and Viatris Successfully Close the Transaction for the Global Research and Development Collaboration". Allschwil....
- [7] Viatris Inc.. (2/28/24). "Press Release: Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance". Pittsburgh, PA....
- [8] Idorsia Ltd.. (2/28/24). "Press Release: Idorsia and Viatris Enter into a Significant Global Research and Development Collaboration". Allschwil....
- [9] Idorsia Ltd.. (7/21/23). "Press Release: Idorsia Announces a Cost Reduction Initiative to Be Implemented by the End of 2023". Allschwil....
- [10] Idorsia Ltd.. (7/20/23). "Press Release: Idorsia Sells Its Asia Pacific (ex-China) Operations – Including Select License Rights to Products – to Sosei Heptares for a Total Consideration of CHF 400 Million". Allschwil....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top